Cargando…

Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin

Insulin therapy often increases body weight and leads to visceral fat accumulation. Progression in diabetes is also associated with accelerated loss of muscle mass. Little is known about body composition changes in type 2 diabetes mellitus (T2DM) patients on insulin therapy who use sodium–glucose co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Yi-Hong, Liu, Sung-Chen, Lee, Chun-Chuan, Sun, Fang-Ju, Liu, Jason J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556548/ https://www.ncbi.nlm.nih.gov/pubmed/36224294 http://dx.doi.org/10.1038/s41598-022-21486-9

Ejemplares similares

Empagliflozin/linagliptin: Euglycaemic diabetic ketoacidosis: case report
Publicado: (2021)

Empagliflozin/linagliptin single‐tablet combination: first‐in‐class treatment option
por: Woo, V.
Publicado: (2015)

The clinical application of linagliptin in Asians
por: Cao, Chu-qing, et al.
Publicado: (2015)

Combination Therapy With Premixed & Basal Insulin Analogues in Asian Indians With Type 2 Diabetes
por: Srivastava, Brijendra Kumar, et al.
Publicado: (2021)

Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine
por: Ott, Christian, et al.
Publicado: (2021)

Combination of Linagliptin and Empagliflozin Preserves Cardiac Systolic Function in an Ischemia-Reperfusion Injury Mice With Diabetes Mellitus
por: Ideishi, Akihito, et al.
Publicado: (2021)

Efficacy and safety of premixed insulin analogs in Asian patients with type 2 diabetes: A systematic review
por: Sheu, Wayne H‐H, et al.
Publicado: (2017)

Comparison of effects of Empagliflozin and Linagliptin on renal function and glycaemic control: a double-blind, randomized clinical trial
por: Mohammad zadeh Gharabaghi, Mohammad Amin, et al.
Publicado: (2022)

Early combination therapy of empagliflozin and linagliptin exerts beneficial effects on pancreatic β cells in diabetic db/db mice
por: Fushimi, Yoshiro, et al.
Publicado: (2021)

Real world outcomes of adding rapid-acting insulin versus switching to analog premix insulin among US patients with type 2 diabetes treated with insulin glargine
por: Miao, Raymond, et al.
Publicado: (2013)

Is There Evidence to Support Use of Premixed or Prandial Insulin Regimens in Insulin-Naive or Previously Insulin-Treated Type 2 Diabetic Patients?
por: Yki-Järvinen, Hannele, et al.
Publicado: (2013)

Initial Combination Empagliflozin and Linagliptin Improves Kidney Fibrotic Marker in Patients With Type 2 Diabetes: A Randomized Controlled Trial
por: Sathavarodom, Nattapol, et al.
Publicado: (2021)

Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting
por: Lee, Yueh-Ting, et al.
Publicado: (2021)

Comparison of the Effect of Glycemic Control in Type 2 Diabetes Outpatients Treated With Premixed and Basal Insulin Monotherapy in China
por: Liu, Guangxu, et al.
Publicado: (2018)

Linagliptin as add-on therapy to insulin for patients with type 2 diabetes
por: von Websky, Karoline, et al.
Publicado: (2013)

Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis
por: Moon, Shinje, et al.
Publicado: (2021)

IDegLira Improves Metabolic Control in Patients with Type 2 Diabetes Previously Treated with Premix Insulin
por: Bostandzic, Amela Dizdarevic, et al.
Publicado: (2022)

Expert Opinion: Patient Selection for Premixed Insulin Formulations in Diabetes Care
por: Kalra, Sanjay, et al.
Publicado: (2018)

Linagliptin Improves Insulin Sensitivity and Hepatic Steatosis in Diet-Induced Obesity
por: Kern, Matthias, et al.
Publicado: (2012)

Diagnostic Accuracy of Glycated Haemoglobin and Average Glucose Values in Type 2 Diabetes Mellitus Treated with Premixed Insulin
por: Walicka, Magdalena, et al.
Publicado: (2019)

Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice
por: Takahashi, Hiroyuki, et al.
Publicado: (2019)

Analytical quality by design based on design space in reversed-phase-high performance liquid chromatography analysis for simultaneous estimation of metformin, linagliptin and empagliflozin
por: Marie, Aya A., et al.
Publicado: (2022)

Linagliptin and Empagliflozin Inhibit Microtubule Affinity Regulatory Kinase 4: Repurposing Anti-Diabetic Drugs in Neurodegenerative Disorders Using In Silico and In Vitro Approaches
por: Atiya, Akhtar, et al.
Publicado: (2023)

Interrelationship of Gut Microbiota, Obesity, Body Composition and Insulin Resistance in Asians with Type 2 Diabetes Mellitus
por: Pai, Che-Sheng, et al.
Publicado: (2022)

Sexual Differences in response to Mid- or Low-Premixed Insulin Analogue in Patients with Type 2 Diabetes
por: Liu, Bing-li, et al.
Publicado: (2020)

Intensification of Insulin Therapy for Type 2 Diabetic Patients in Primary Care: Basal-Bolus Regimen Versus Premix Insulin Analogs: When and for whom?
por: Mosenzon, Ofri, et al.
Publicado: (2013)

The efficacy and safety of combined GLP-1RA and basal insulin therapy among inadequately controlled T2D with premixed insulin therapy
por: Liu, Jhih-Syuan, et al.
Publicado: (2023)

SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in db/db Mice, a Model of Type 2 Diabetes
por: Korbut, Anton I., et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Linagliptin in Japan Based on Results from the Asian Subpopulation in the CARMELINA(®) Trial
por: Watada, Hirotaka, et al.
Publicado: (2020)

Twice-daily insulin degludec/insulin aspart effectively improved morning and evening glucose levels and quality of life in patients previously treated with premixed insulin: an observational study
por: Fujimoto, Kanta, et al.
Publicado: (2018)

Linagliptin: from bench to bedside
por: Doupis, John
Publicado: (2014)

The Effect of DPP4 Inhibitor on Glycemic Variability in Patients with Type 2 Diabetes treated with twice-daily Premixed Human Insulin*
por: Tan, Florence Hui Sieng, et al.
Publicado: (2021)

Comparison of Basal-Bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes
por: Bellido, Virginia, et al.
Publicado: (2015)

Basal-bolus or premixed? Shedding light on optimal insulin regime for type 1 diabetes
por: Louise Walton, Emma
Publicado: (2018)

Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations
por: Ceriello, Antonio, et al.
Publicado: (2016)

Effects of mulberry twig alkaloids(Sangzhi alkaloids) and metformin on blood glucose fluctuations in combination with premixed insulin-treated patients with type 2 diabetes
por: Meng, Ziyu, et al.
Publicado: (2023)

Practical Guidance on the Use of Premix Insulin Analogs in Initiating, Intensifying, or Switching Insulin Regimens in Type 2 Diabetes
por: Wu, Ted, et al.
Publicado: (2015)

Comparative assessment of the efficacy and safety of acarbose and metformin combined with premixed insulin in patients with type 2 diabetes mellitus
por: Wu, Honghua, et al.
Publicado: (2017)

Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin
por: Aravind, S. R., et al.
Publicado: (2022)

Association of diabetic ketoacidosis, severe hypoglycemia and glycemic control among children and young adults with type 1 diabetes mellitus treated with premixed versus basal-bolus insulin therapy
por: Chou, Wei-Yu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_55pfkc15u6j3bg8iid4mtenrtu